Does cardiovascular therapy affect the onset and recurrence of preretinal and vitreous haemorrhage in diabetic eye disease?

被引:10
作者
Banerjee, S
Denniston, AKO
Gibson, JM
Dodson, PM [1 ]
机构
[1] Birmingham Heartlands & Solihull NHS Trust, Birmingham B9 5SS, W Midlands, England
[2] Birmingham & Midland Eye Ctr, Birmingham, W Midlands, England
关键词
vitreous haemorrhage; diabetic retinopathy; aspirin; statin;
D O I
10.1038/sj.eye.6701338
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Aims To review the role of cardiovascular disease and therapy in the onset and recurrence of preretinal/vitreous haemorrhage in diabetic patients. Methods Retrospective case note analysis of diabetic patients with vitreous haemorrhage from the Diabetic Eye Clinic at Birmingham Heartlands Hospital. Results In total, 54 patients (mean age 57.1, 37 males, 20 type I vs 34 type II diabetic patients) were included. The mean (SD) duration of diagnosed diabetes at first vitreous haemorrhage was significantly longer, 21.9 (7.6) years for type I and 14.8 (9.3) years for type II diabetic patients (P<0.01, unpaired t-test, two-tailed). Aspirin administration was not associated with a significantly later onset of vitreous haemorrhage. Four episodes were associated with ACE-inhibitor cough. There was a trend towards HMGCoA reductase inhibitor (statin) use being associated with a delayed onset of vitreous haemorrhage: 21.4 years until vitreous haemorrhage (treatment group) vs 16.2 years (nontreatment group) (P = 0.09, two-tailed, unpaired t-test, not statistically significant). During follow-up 56 recurrences occurred, making a total of 110 episodes of vitreous haemorrhage in 79 eyes of 54 patients. The mean (range) follow-up post haemorrhage was 1067 (77-3842) days, with an average of 1.02 recurrences. Age, gender, diabetes type (I or II) or control, presence of hypertension or hypercholesterolaemia, and macrovascular complications were not associated with a significant effect on the 1-year recurrence rate. Aspirin (and other antiplatelet or anticoagulant agents) and ACE-inhibitors appeared to neither increase nor decrease the 1-year recurrence rate. However, statin use was significantly associated with a reduction in recurrence (Fisher exact P<0.05; two-tailed) with an odds ratio (95% CI) of 0.25 (0.1-0.95). Conclusion In this retrospective analysis, the onset of preretinal/ vitreous haemorrhage was not found to be accelerated by gender, hypertension, hypercholesterolaemia, evidence of macrovascular disease, or HbA1c. Neither aspirin nor ACE-inhibitor administration accelerated the onset or recurrence of first vitreous haemorrhage. Statins may have a protective role, both delaying and reducing the recurrence of haemorrhage.
引用
收藏
页码:821 / 825
页数:5
相关论文
共 18 条
  • [1] Systemic considerations in the management of diabetic retinopathy
    Aiello, LP
    Cahill, MT
    Wong, JS
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 2001, 132 (05) : 760 - 776
  • [2] ALHUSAINY S, 2004, IN PRESS EYE
  • [3] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS
    ALTMAN, R
    CARRERAS, L
    DIAZ, R
    FIGUEROA, E
    PAOLASSO, E
    PARODI, JC
    CADE, JF
    DONNAN, G
    EADIE, MJ
    GAVAGHAN, TP
    OSULLIVAN, EF
    PARKIN, D
    RENNY, JTG
    SILAGY, C
    VINAZZER, H
    ZEKERT, F
    ADRIAENSEN, H
    BERTRANDHARDY, JM
    BRAN, M
    DAVID, JL
    DRICOT, J
    LAVENNEPARDONGE, E
    LIMET, R
    LOWENTHAL, A
    MORIAU, M
    SCHAPIRA, S
    SMETS, P
    SYMOENS, J
    VERHAEGHE, R
    VERSTRAETE, M
    ATALLAH, A
    BARNETT, H
    BATISTA, R
    BLAKELY, J
    CAIRNS, JA
    COTE, R
    CROUCH, J
    EVANS, G
    FINDLAY, JM
    GENT, M
    LANGLOIS, Y
    LECLERC, J
    NORRIS, J
    PINEO, GF
    POWERS, PJ
    ROBERTS, R
    SCHWARTZ, L
    SICURELLA, J
    TAYLOR, W
    THEROUX, P
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921): : 81 - 100
  • [4] CARDIOVASCULAR-DISEASE RISK PROFILES
    ANDERSON, KM
    ODELL, PM
    WILSON, PWF
    KANNEL, WB
    [J]. AMERICAN HEART JOURNAL, 1991, 121 (01) : 293 - 298
  • [5] Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
  • [6] EFFECTS OF ASPIRIN ON VITREOUS PRERETINAL HEMORRHAGE IN PATIENTS WITH DIABETES-MELLITUS - EARLY TREATMENT DIABETIC-RETINOPATHY STUDY REPORT NO-20
    CHEW, EY
    KLEIN, ML
    MURPHY, RP
    REMALEY, NA
    FERRIS, FL
    [J]. ARCHIVES OF OPHTHALMOLOGY, 1995, 113 (01) : 52 - 55
  • [7] The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy?
    Chowdhury, T
    Hopkins, D
    Dodson, PM
    Vafidis, GC
    [J]. EYE, 2002, 16 (06) : 689 - 693
  • [8] For debate - Preventing atherosclerotic events with aspirin
    Cleland, JGF
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2002, 324 (7329): : 103 - 105
  • [9] Design of the collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes
    Colhoun, HM
    Thomason, MJ
    Mackness, MI
    Maton, SM
    Betteridge, DJ
    Durrington, PN
    Hitman, GA
    Neil, HAW
    Fuller, JH
    [J]. DIABETIC MEDICINE, 2002, 19 (03) : 201 - 211
  • [10] Medical treatment of diabetic retinopathy
    Donaldson, M
    Dodson, PM
    [J]. EYE, 2003, 17 (05) : 550 - 562